Overview

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Status:
Completed

Trial end date:
2015-04-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Tenofovir